Our previous work indicates that the intrathecal administration of neuropeptide Y (NPY) acts at its cognate receptors to reduce behavioral signs of nociception in several models of inflammatory pain, including the formalin test. The present study extends these findings to a rat model of peripheral neuropathic pain, and then evaluates the hypothesis that NPY inhibits inflammation-and nerve injury-induced activation of spinal nociceptive transmission. Here we show that NPY dose-dependently reduced behavioral signs of mechanical and cold hypersensitivity in the spared nerve injury (SNI) model. Intrathecal administration of either a Y1 (BIBO3304) or a Y2 (BIIE0246) receptor antagonist dose-dependently reversed the anti-allodynic actions of NPY. To monitor the effects of NPY on the stimulus-induced activation of spinal nociresponsive neurons, we quantified protein expression of the immediate-early gene cfos in lamina I-VI of the L4-L5 dorsal horn, with special attention to the mediolateral pattern of Fos immunohistochemical staining after SNI. Either tactile stimulation of the hindpaw ipsilateral to nerve injury, or intraplantar injection of noxious formalin, increased the number of Fos-like immunoreactive profiles. Tactile stimulation evoked a mediolateral pattern of Fos expression corresponding to the innervation territory of the uninjured (sural) nerve. We found that intrathecal NPY reduced both formalin-and SNI-induced Fos expression. NPY inhibition of SNI-induced Fos expression was localized to the sural (uninjured) innervation territory, and could be blocked by intrathecal BIBO3304 and BIIE0246. We conclude that NPY acts at spinal Y1 and Y2 receptors to reduce spinal neuron activity and behavioral signs of inflammatory or neuropathic pain. Ó
Introduction
Neuropeptide Y (NPY) is an abundant and widespread neuroactive peptide that exerts numerous physiological actions, including pain modulation. NPY and its Y1 and Y2 receptors are located at key pain signalling centers throughout the nervous systems, particularly the dorsal horn of the spinal cord [15, 17] . Several studies indicate that NPY, when administered at the spinal level, inhibits transient or inflammatory pain [36, 43] . For example, intrathecal administration of NPY Y2 receptor agonists reduces not only behavioral responsiveness to noxious heat [16, 42] , but also the hyperalgesia associated with inflammation [23, 42] . Much less clear are the effects of NPY receptor agonists in models of neuropathic pain. Evidence from pharmacological studies suggests that intrathecally applied Y1 and Y2 agonists attenuate the flexor reflex in axotomized animals [50] , but comparable studies in behavioral models of partial peripheral nerve injury are not available. Therefore, the present studies were designed to determine whether intrathecal administration of NPY dose-dependently reduces behavioral signs of neuropathic pain, and whether such effects are mediated by 
